Shire Pharmaceuticals and FTSE

Smith Nephew: Boardroom bosses will be trying to gauge whether the revolts, which got this year season off to a blistering start, can be maintained, according to The Guardian. With BP and Smith & Nephew still reeling from No votes at the start of April, Shire Pharmaceuticals and fellow FTSE 100 member CRH were last week rebuked by investors, while in the FTSE 250, engineering firm Weir had to abandon plans to issue shares to its directors after a resounding protest. Rakesh Kapoor package – twice what he received the year before – has been described by one shareholder as a misjudgment of the mood of investors, who have marked 2016 as the year they are prepared to say no to exorbitant pay deals. This AGM season is shaping up to be the most raucous on record, said Simon Walker, director general of the Institute of Directors. The mood appears to be hardening even compared with the so-called shareholder spring of 2012, which delivered boardrooms their first jolt since May 2003 – when Glaxo Smith-Kline £22m deal for then chief Jean-Pierre Garnier was rejected. I welcome the fact that shareholders are finding their voice. (news.financializer.com). As reported in the news.